MedTrace Logo

Relative Potency of Inhaled Corticosteroids

NCT00292838 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-07-20

No results posted yet for this study

Summary

To investigate the validity of a clinical model to determine the relative potency of different preparations of inhaled corticosteroids used for the treatment of asthma or of eosinophilic bronchitis without asthma.

Conditions

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

fluticasone 25, 50, 100, 200 mcg

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • St. Joseph's Healthcare Hamilton

    lead OTHER

Principal Investigators

  • Frederick E Hargreave, MD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2007-02-28
Completion
2007-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00292838 on ClinicalTrials.gov